Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Abstract excerpt

Thrombosis remains a major unmet need in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), accounting for three to four-fold higher probability of risk compared to controls [ 1 ]. In PMF, this risk is poorly characterized given that, unlike PV and ET, death due to disease progression and/or evolution to leukemia represents a competing risk that significantly overwhelms that...